NO20045234L - 2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer - Google Patents

2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer

Info

Publication number
NO20045234L
NO20045234L NO20045234A NO20045234A NO20045234L NO 20045234 L NO20045234 L NO 20045234L NO 20045234 A NO20045234 A NO 20045234A NO 20045234 A NO20045234 A NO 20045234A NO 20045234 L NO20045234 L NO 20045234L
Authority
NO
Norway
Prior art keywords
vla
quinolinyl
processes
preparation
inhibitors
Prior art date
Application number
NO20045234A
Other languages
English (en)
Norwegian (no)
Inventor
Marie-Agnes Lassoie
Sylvain Routier
Luc Quere
Laurent Knerr
Thierry Demaude
Francoise De Laveleye-Defais
Thierry Kogej
Gerald Guillaumet
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO20045234L publication Critical patent/NO20045234L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
NO20045234A 2002-04-30 2004-11-29 2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer NO20045234L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02009746 2002-04-30
PCT/EP2003/003909 WO2003093237A1 (en) 2002-04-30 2003-04-15 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors

Publications (1)

Publication Number Publication Date
NO20045234L true NO20045234L (no) 2005-01-18

Family

ID=29286106

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045234A NO20045234L (no) 2002-04-30 2004-11-29 2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer

Country Status (24)

Country Link
US (2) US7638630B2 (xx)
EP (2) EP1870402A1 (xx)
JP (1) JP2005535583A (xx)
KR (1) KR100841165B1 (xx)
CN (2) CN101200450A (xx)
AR (1) AR039341A1 (xx)
AT (1) ATE384699T1 (xx)
AU (1) AU2003232472B2 (xx)
BR (1) BR0309719A (xx)
CA (1) CA2484954C (xx)
CO (1) CO5450243A1 (xx)
CU (1) CU23415B7 (xx)
DE (1) DE60318839T2 (xx)
ES (1) ES2298543T3 (xx)
IL (1) IL164516A0 (xx)
MX (1) MXPA04010673A (xx)
MY (1) MY135218A (xx)
NO (1) NO20045234L (xx)
NZ (1) NZ536180A (xx)
PL (1) PL373763A1 (xx)
RU (1) RU2315041C2 (xx)
TW (2) TWI268278B (xx)
WO (1) WO2003093237A1 (xx)
ZA (1) ZA200408447B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003232472B2 (en) * 2002-04-30 2008-09-18 Ucb Pharma 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
ES2548419T3 (es) * 2003-02-20 2015-10-16 Ajinomoto Co., Inc. Procedimiento para producir un derivado de fenilalanina que tiene esqueleto de quinazolindiona e intermedio para el mismo
US7145005B2 (en) 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
AU2006254772B2 (en) * 2005-06-09 2011-06-02 Ucb Pharma S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
JP4898635B2 (ja) 2006-11-14 2012-03-21 参天製薬株式会社 置換フェニルアミノ低級アルキル基とエステル構造を導入したフェニル基を置換基として有する新規１，２−ジヒドロキノリン誘導体
WO2008125210A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases
WO2008125215A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138592A1 (en) * 2007-05-14 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138615A1 (en) * 2007-05-16 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2009074829A1 (en) * 2007-12-12 2009-06-18 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
EP2085407A1 (en) 2008-02-04 2009-08-05 Sahltech I Göteborg AB Treatment of idiopathic thrombocytopenic purpura
CN102089283B (zh) * 2008-05-12 2015-11-25 步制药股份有限公司 含有具有取代氧基的2，2，4-三甲基-6-苯基-1，2-二氢喹啉衍生物的糖皮质激素受体激动剂
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US20150368213A1 (en) * 2014-06-20 2015-12-24 The University of Montana, Missoula, MT Novel Inhibitors of System Xc-
CA3121986C (en) * 2014-12-24 2024-04-09 Lg Chem, Ltd. Biaryl derivative as gpr120 agonist
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4284947A1 (en) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2920741B2 (ja) * 1994-12-14 1999-07-19 参天製薬株式会社 新規１，３−ジアルキルウレア誘導体
DE69528197T2 (de) * 1994-12-14 2003-06-05 Santen Pharmaceutical Co Ltd Neue 1,3-dialkylharnstoff-derivate
JPH0987291A (ja) * 1995-09-26 1997-03-31 Wakamoto Pharmaceut Co Ltd 新規なアラニン誘導体
CA2279977A1 (en) 1997-02-04 1998-08-06 John S. Kiely 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
HU229362B1 (en) * 1997-08-22 2013-11-28 Hoffmann La Roche N-alkanoylphenylalanine derivatives
AU754557B2 (en) * 1998-08-26 2002-11-21 Aventis Pharma Limited Aza-bicycles which modulate the inhibition of cell adhesion
WO2000066572A1 (en) * 1999-04-28 2000-11-09 Dr. Reddy's Research Foundation Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
US6280442B1 (en) * 1999-09-01 2001-08-28 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US6399599B1 (en) * 1999-10-13 2002-06-04 Novartis Ag Substituted 2-oxo-1,4-diazacycloalkanes
AU2003232472B2 (en) * 2002-04-30 2008-09-18 Ucb Pharma 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
AU2006254772B2 (en) 2005-06-09 2011-06-02 Ucb Pharma S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament

Also Published As

Publication number Publication date
TWI267508B (en) 2006-12-01
ES2298543T3 (es) 2008-05-16
BR0309719A (pt) 2005-02-09
AU2003232472B2 (en) 2008-09-18
MY135218A (en) 2008-02-29
DE60318839D1 (de) 2008-03-13
ZA200408447B (en) 2006-07-26
KR20040106425A (ko) 2004-12-17
EP1501801B1 (en) 2008-01-23
EP1870402A1 (en) 2007-12-26
US20100105681A1 (en) 2010-04-29
PL373763A1 (en) 2005-09-19
MXPA04010673A (es) 2005-09-30
CN101200450A (zh) 2008-06-18
IL164516A0 (en) 2005-12-18
US20080064720A1 (en) 2008-03-13
KR100841165B1 (ko) 2008-06-24
TWI268278B (en) 2006-12-11
CA2484954C (en) 2010-02-09
WO2003093237A1 (en) 2003-11-13
CO5450243A1 (es) 2004-10-29
US7638630B2 (en) 2009-12-29
EP1501801A1 (en) 2005-02-02
CN1649842A (zh) 2005-08-03
ATE384699T1 (de) 2008-02-15
NZ536180A (en) 2005-04-29
AR039341A1 (es) 2005-02-16
AU2003232472A1 (en) 2003-11-17
CU23415B7 (es) 2009-09-08
RU2004135304A (ru) 2005-07-10
RU2315041C2 (ru) 2008-01-20
TW200404061A (en) 2004-03-16
TW200616960A (en) 2006-06-01
CA2484954A1 (en) 2003-11-13
DE60318839T2 (de) 2009-01-22
JP2005535583A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
NO20045234L (no) 2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer
ECSP067057A (es) Nuevos derivados de piridazin-3(2h)-ona
NO20080125L (no) 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament
CN106083847B (zh) 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
SG155909A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
CL43596B (es) Compuestos derivados de pirimidina; composicion farmaceutica; y su uso para tratar o prevenir un trastorno o enfermedad relacionado con la actividad de crth2, tales como asma, rinitis alergica, dermatitis, atopica y conjuntivitis alergica.
DK0672031T3 (da) Catecholdiethere som selektive PDE IV-inhibitorer
BR0010607A (pt) Derivados de piperidina úteis como antagonistas de ccr5
NO20054878L (no) 2-Fenoksy- og 2-fenylsulfonamidderivater med CCR3-antagonistisk aktivitet for behandling av astma og andre inflammasjons- eller immunologiske forstyrrelser
NO20084005L (no) Aminderivater
NO20063928L (no) Substituerte kinolinforbindelser
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
MEP60508A (en) Acylated arylcycloalkylamines and their use as pharmaceuticals
NO20085212L (no) Nye pyridinanaloger
BRPI0508927A (pt) compostos úteis para o tratamento de doenças
Fu et al. Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors
NO20064114L (no) Fremgangsmate for fremstilling av N-arylpiperazinderivater
UA90319C2 (ru) Соединения 2,6-хинолинила и их применение как лекарственного средства
TW200745087A (en) CCR5 antagonists useful for treating HIV
HUP0302121A2 (hu) {[(Biciklil- vagy heterobiciklil-metil)-szulfonil]-alkil}-csoporttal szubsztituált N-hidroxi-formamidok, eljárás előállításukra, intermedierek és a vegyületeket tartalmazó gyógyszerkészítmények
PT1406865E (pt) Derivados de acido succinico
HUP0401678A2 (hu) 2-Amino-6-(2,4,5-szubsztituált-fenil)piridin-származékok és alkalmazásuk nitrogén(II)oxid szintáz inhibitorként és ezeket tartalmazó gyógyszerkészítmények
KR19990008408A (ko) 신규 피리딘 유도체 및 이를 유효성분으로 하는 의약